506648552 05/06/2021

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6695363

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
QIN YAN	07/16/2020

RECEIVING PARTY DATA

Name:	OXIDIEN PHARMACEUTICALS, LLC	
Street Address:	747 SW 2ND AVE., SUITE 204	
City:	GAINESVILLE	
State/Country:	FLORIDA	
Postal Code:	32601	

PROPERTY NUMBERS Total: 1

Property Type	Number	
Application Number:	15563828	

CORRESPONDENCE DATA

Fax Number: (407)926-7720

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4079267726

Email: ktissue@savvyIPlaw.com

Correspondent Name: WOLTER VAN DYKE DAVIS, PLLC

Address Line 1: 1900 SUMMIT TOWER BLVD., SUITE 140

Address Line 4: ORLANDO, FLORIDA 32810

ATTORNEY DOCKET NUMBER:	11922-006US	
NAME OF SUBMITTER:	TIMOTHY H. VAN DYKE	
SIGNATURE:	/Timothy H. Van Dyke/	
DATE SIGNED:	05/06/2021	

Total Attachments: 3

source=Oxidien assignment signed by QY#page1.tif source=Oxidien assignment signed by QY#page2.tif source=Oxidien assignment signed by QY#page3.tif

PATENT 506648552 REEL: 056155 FRAME: 0743

DocuSign Envelope ID: 54574ED6-1D20-4E91-ACD6-049381936603

Yan Oxidien Assignment

ASSIGNMENT

WHEREAS, I understand pursuant to that certain Redemption and Contribution

Agreement, dated as of November 12, 2019, by and among, inter alios, Captozyme Inc. ("

Captozyme") and Oxidien Pharmaceuticals, LLC ("Oxidien"), certain assets of Captozyme,

including the IP, were contributed to Oxidien;

WHEREAS, Oxidien has requested, and I have agreed, to enter into this Assignment to

memorialize my assignment of any right, title and interest to the applications enumerated in

Appendix A, and all subject matter disclosed and claimed therein to Oxidien as successor in

interest to Captozyme with respect to the IP;

NOW, THEREFORE, in exchange for a 1.25% membership interest in Oxidien memorized

by a Subscription Agreement and a separately executed Amended and Restated Limited Liability

Company Agreement among Oxidien and members named therein including I, and for other good

and valuable consideration, the receipt and sufficiency of which I hereby acknowledge, I:

Qin YAN

of Rockville, Maryland

hereby assign any and all of my rights, title and interests in and to the patent assets enumerated in

Appendix A, and all subject matter described therein invented and originated by me (collectively

"the Invention") to OXIDIEN PHARMACEUTICALS, LLC, its successors and assigns and all

other patent applications and patents for the Invention which may be applied for or granted,

including, all divisional, continuing, substitute, renewal, reissue, reexamination, counterpart,

substitute, extension, and all other application for letters patent which are or have been filed for

the inventions described and claimed in the United States, its territorial possessions, and all foreign

countries with the exception of EPO member countries and in all patents and extensions which

may be granted for the Application.

In addition, to the extent needed to transfer valid patent rights in any given country, I assign all

rights to claim the benefit of priority resulting from the filing of the '937 APP and '976 APP as so

named in Appendix A, and authorize and request any official whose duty it is to issue patents, to

PATENT REEL: 056155 FRAME: 0744 PHARMACEUTICALS, LLC, or its successors or assigns and agree that on request and at the expense of OXIDIEN PHARMACEUTICALS, LLC to reasonably compensate for my time and expenses, I will communicate to OXIDIEN PHARMACEUTICALS, LLC. or its representatives or nominees any facts known to me respecting said inventions and improvements and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuation, reexamination and reissue applications, make all rightful oaths sufficient to aid OXIDIEN PHARMACEUTICALS, LLC, its successors, assigns, and nominees to obtain and enforce proper patent protection for said invention and its improvements in all countries with the exception of EPO member countries.

Signature:	Qin Y AN	Date:	<u> 16 July 2020</u>
Signature:	Helens Cowley Melens Cowley, CEO Oxidien Pharmaceuticals, LLC	Date:	9/14/2020

RECORDED: 05/06/2021

APPENDIX A-Assets assigned to Oxidien Pharmaceuticals, LLC

Application No.
Australian Patent Application No. 2016244121
Canadian Patent Application No. 2,984,763
Chinese Patent Application No. 201680030901.2
Indian Patent Application No. 201717039146
Korean Patent Application No. 10-2017-7031741
PCT Application No. PCT/US2016/025937 (*937 App)
U.S. Patent Application No. 15/563,828
U.S. Provisional Patent Application No. 62/141,976 (*976 App)

PATENT REEL: 056155 FRAME: 0746